Generic and Biosimilar Cancer Medicines
Estimated value
—
Awarded value
—
Suppliers
67
Lots
33
Published
21 Apr 2023
Description
This Framework Agreement is for the supply of generic and biosimilar cancer medicines to NHS Scotland. The Goods were separated into forty-one (41) categories, each of which is identified as a “Lot”. Full details of each awarded Lot is contained in section II.2 of this Notice.
Scope
- Reference
- NP39722
- Commercial tool
- Standalone contract
- Contract dates
The Authority is entitled at its sole discretion to extend the Framework Agreement for up to a maximum of twenty four (24) months by giving a minimum of three (3) months written notice of such extension(s).
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- Scotland
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Logistics | 5 | quality | — |
| — | 95 | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 33 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Lots · 33 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | Lot 1 Bendamustine Powder For Solution For Infusion | £95k | cancelled |
| 2 | Lot 2 Capecitabine Tablets | £911k | cancelled |
| 3 | Lot 3 Carboplatin Injection | £597k | cancelled |
| 4 | Lot 4 Cisplatin Injection | £186k | cancelled |
| 5 | Lot 5 Cyclophosphamide Injection, Powder For Reconstitution | £267k | cancelled |